Financière de Tubize SA Ret. no patrimônio
Qual é o Ret. no patrimônio de Financière de Tubize SA?
O Ret. no patrimônio de Financière de Tubize SA é 9.88%
Qual é a definição de Ret. no patrimônio?
O retorno sobre o patrimônio é uma medida da lucratividade de um negócio em relação ao valor contábil do patrimônio líquido. É calculado pela divisão do lucro líquido do exercício pelo total do patrimônio líquido.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. no patrimônio de empresas na Setor Health Care em EURONEXT em comparação com Financière de Tubize SA
O que Financière de Tubize SA faz?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Empresas com ret. no patrimônio semelhantes a Financière de Tubize SA
- Genesys International tem Ret. no patrimônio de 9.87%
- Generix SA tem Ret. no patrimônio de 9.87%
- ACC tem Ret. no patrimônio de 9.87%
- Navigator Global Investments tem Ret. no patrimônio de 9.87%
- Boiron SA tem Ret. no patrimônio de 9.87%
- Boiron SA tem Ret. no patrimônio de 9.87%
- Financière de Tubize SA tem Ret. no patrimônio de 9.88%
- Sical Logistics tem Ret. no patrimônio de 9.88%
- B.L. Kashyap and Sons tem Ret. no patrimônio de 9.89%
- Xilam Animation SA tem Ret. no patrimônio de 9.89%
- Xilam Animation tem Ret. no patrimônio de 9.89%
- Gillanders Arbuthnot and tem Ret. no patrimônio de 9.89%
- Sodifrance SA tem Ret. no patrimônio de 9.89%